As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new vaccines will be available.

“This usual chain of decisions … has been disrupted. And without clarity and coordination, millions may not be able to have ...

James Brumley has positions in Coca-Cola. The Motley Fool has positions in and recommends Amazon, Equifax, MercadoLibre, ...

Pfizer Inc faces a new challenge as Enanta Pharmaceuticals sues over a patent infringement concerning Paxlovid in the EU.

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a ...

AI is making an impact in the early stages of drug discovery. It can scan huge chemical and biological datasets, predict how ...

In the fourth part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, discusses how healthcare ...

Padcev-Keytruda will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Pfizer stock currently trades at very low volatility. That could mean it’s ripe for a breakout trade, like a long strangle.

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate PFE stock a Sell.